Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Study ID
- NCT00429065
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 15 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
Study Details
The purpose of this study is to determine whether a specific subtype of lymphoma responds optimally to treatment with rituximab and chemotherapy.
Key Dates
- Start date
- Jan 31, 2007
- Status verified
- Jan 2007
- Completion
- Jan 31, 2007
Study Design
- Enrollment
- 30 participants
Central Contacts
- Silvia Rivas-Vera, MD56 28 04 46
- Pedro Sobrevilla-Calvo, MD56 28 04 16
Related Studies
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLPHASE2 · Recruiting · New York Medical College · Valhalla, New York
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsPHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin